Abstract
Importance The immunogenicity of COVID-19 booster vaccine following inactivated or chimpanzee adenoviral vector COVID-19 vaccination is unclear.
Objectives To determine the reactogenicity and immunogenicity of different booster vaccine following CoronaVac (by Sinovac) or ChAdOx1 (by AstraZeneca) primary series vaccination.
Design Prospective, non-randomized, open-labeled cohort study
Setting A single center, tertiary care university-based hospital in Bangkok.
Participants Healthy adults who received a 2-dose homologous primary series of either CoronaVac or ChAdOx1 8-12 weeks earlier.
Intervention One of the four booster vaccines: BBIBP-CorV (by Sinopharm), ChAdOx1, 30μg-BNT162b2 (by Pfizer) or 15μg-BNT162b2 vaccines.
Main Outcomes and Measures Self-reported adverse events (AEs) for 7 days following vaccination were collected by electronic diary system. The immunogenicity was determined by IgG against receptor binding domain (RBD) of the SARS-CoV-2 spike protein, 50% plaque reduction neutralization test (PRNT50) against Delta and Beta variants, 50% pseudovirus neutralizing antibody (PVNT50) against Delta and Omicron variants, and whole blood interferon gamma (IFN-□) releasing assay.
Results Among the 352 participants (179 in CoronaVac- and and 173 in ChAdOx1-prime group), 285 (81%) were female, and the median age was 39 (interquartile range: 31-47) years. The AEs for all booster vaccines were mild to moderate. Two weeks post-booster, 30μg-BNT162b2 induced the highest anti-RBD IgG concentration in the CoronaVac- and ChAdOx1-prime groups (5152 and 2364 BAU/mL), followed by 15μg-BNT162b2 (3981 and 1962 BAU/mL), ChAdOx1 (1358 and 246 BAU/mL), and BBIBP-CorV (154 and 128 BAU/mL), respectively. The PRNT50 against the Delta variant were also highest with 30μg-BNT162b2 (411 and 470) and 15μg-BNT162b2 (499 and 358); followed by ChAdOx1 (271 and 69), and BBIBP-CorV (61.3 and 49) for CoronaVac and ChAdOx1-prime, respectively. Similar trend was observed for PRNT50 against the Beta variant. The PVNT50 against the Omicron variant was highest with 30μg-BNT162b2 (543 and 521) followed by 15μg-BNT162b2 (551 and 232) for CoronaVac- and ChAdOx1-prime, respectively. BNT162b2 vaccine also induced the highest IFN-□ response in both CoronaVac- and ChAdOx1-prime groups.
Conclusions and Relevance Heterologous boosting vaccination with BNT162b2 following CoronaVac or ChAdOx1 primary series is the most immunogenic against SARS-CoV-2 variants. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.
Trial Registration Thaichinicaltrials.org (TCTR20210719006).
Question Which COVID-19 booster vaccine is most immunogenic following 2-dose CoronaVac or ChAdOx1 primary series?
Findings This prospective cohort study found that BNT162b2 given half or standard dosage as a booster (3rd dose) vaccination induced the highest humoral responses against the original SARS-CoV-2 Wuhan strain, and the SARS-CoV-2 variants (Delta, Beta, and Omicron). Boosting with inactivated vaccine (BBIBP-CorV) induced poor humoral and cellular immune responses.
Meaning Heterologous boosting with half or standard dosage of BNT162b2 following CoronaVac or ChAdOx1 primary series is safe and highly immunogenic, and likely to confer protection against the SARS-CoV-2 variants.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
TCTR20210719006
Funding Statement
This study was supported by the National Research Council of Thailand. The Abbott Laboratories Ltd. partially supported the reagents for the anti-SARS-CoV-2 RBD IgG in this study. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Siriraj Institutional Review Board, Thailand (COA no. Si 537/2021).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
